122: CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

Background: Studies indicate SBRT treatment of oligometastatic disease is associated with higher rates of local control with acceptably toxicity [1,2]. A lack of randomised data in this area limits interpretation, preventing evaluation of the true benefit of adding SBRT to systemic therapy in this context. CORE investigates whether adding SBRT to standard therapy improves patient outcomes in common primary tumour sites where oligometastatic disease is encountered (NSCLC, breast and prostate). CORE aims to demonstrate: (1) feasibility of recruitment, (2) deliverability in a multi-centre setting and (3) activity of SBRT based on progression free survival (PFS) across three tumour types.